The Pharma Letter Podcast — Episode 16 — EQRx plots radical disruption on pricing

Simon Wentworth

22 July 2022

episode16_big

More on this story...

Focus on access helps EQRx find receptive audience in the UK

20 October 2021

EQRx releases positive Phase III trial data on sugemalimab

8 August 2022

Not so easy to go low with drug prices, EQRx accepts

11 November 2022

EQRx gets MAA for aumolertinib accepted by EMA

2 December 2022

Companies featured in this story

More ones to watch >

Today's issue

Amgen names new president of research

Amgen names new president of research

21 November 2024

Vyriad collaborates with Novartis on in vivo CAR-T cell therapies

21 November 2024

EC approval for Pfizer’s Hympavzi

20 November 2024

Flagship reveals new agreements under Pfizer link-up

20 November 2024

Ascentage's lisaftoclax accepted for priority review in China

20 November 2024

Xbrane and Intas to jointly develop Opdivo biosimilar

20 November 2024

Chris Boshoff takes on new role at Pfizer

20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

More Features in Biotechnology

Vyriad collaborates with Novartis on in vivo CAR-T cell therapies

21 November 2024

EC approval for Pfizer’s Hympavzi

20 November 2024

Flagship reveals new agreements under Pfizer link-up

20 November 2024

Two Neds better than one in Jupiter’s world of moons

20 November 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze